Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. Company
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Novavax, Inc.
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Number of employees : 791 people.
Sales per Business
20192020Delta
Recombinant Vaccines18.66100%475.60100% +2448.48%
USD in Million
Sales per region
20192020Delta
United States18.66100%475.60100% +2448.48%
USD in Million
Managers
Name Title Age Since
Stanley Erck President, Chief Executive Officer & Director 72 2011
James Kelly Chief Financial Officer, Treasurer & Executive VP 54 2021
Gregory Glenn President-Research & Development 66 2016
Biegie Lee Chief Information Officer & Senior Vice President - 2020
Gale Smith Chief Scientist & Senior Vice President-Discovery - 2021
Filip Dubovsky Chief Medical Officer & Executive Vice President - 2020
Richard Crowley Chief Operating Officer & Executive Vice President 63 2020
Troy Morgan Chief Compliance Officer & Senior Vice President - 2021
Michael A. McManus Independent Director 77 1998
James Young Chairman 67 2011
Members of the board
Name Title Age Since
James Young Chairman 67 2011
Michael A. McManus Independent Director 77 1998
Rajiv Indravadan Modi, Dr. Director 60 2009
Stanley Erck President, Chief Executive Officer & Director 72 2011
Richard H. Douglas, Dr. Independent Director 67 2010
Rachel K. King Independent Director 60 2018
David M. Mott Independent Director 54 2020
Gregg Alton Independent Director 54 2020
Margaret G. McGlynn Independent Director 60 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 74,893,155 73,929,575 98.7% 0 0.0% 98.7%
Shareholders
NameEquities%
The Vanguard Group, Inc. 6,556,274 8.80%
Fidelity Management & Research Co. LLC 4,811,313 6.46%
RA Capital Management LP 2,559,918 3.44%
BlackRock Fund Advisors 1,725,815 2.32%
SSgA Funds Management, Inc. 1,693,390 2.27%
Franklin Advisers, Inc. 1,088,520 1.46%
Perceptive Advisors LLC 1,043,000 1.40%
Geode Capital Management LLC 882,728 1.19%
Citadel Advisors LLC 683,468 0.92%
Renaissance Technologies LLC 672,683 0.90%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Novavax, Inc.
Sector Other Biotechnology & Medical Research